SecBot SecBot
SECBOTREPLAY Home › Report › SYRE

SYRE · Spyre Therapeutics announced positive 12-week induction topline data…

Spyre Therapeutics, Inc. · 8-K filed Jun 15, 2026 at 08:01 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jun 15, 2026 at 08:01 ET

Spyre Therapeutics announced positive 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY002 (anti-TL1A) in moderate-to-severe ulcerative colitis. The primary endpoint was met with a statistically significant 10.7-point reduction in Robarts Histopathology Index (RHI) score (p<0.0001), with clinical remission of 33% and endoscopic improvement of 42%. Safety was consistent with the TL1A class with no drug-related serious adverse events. This de-risks SPY002 and supports the ongoing Part B randomized portion and combination arms.

  • Primary endpoint met: 10.7-point reduction in RHI from baseline at Week 12 (p<0.0001)
  • Clinical remission rate of 33% and endoscopic improvement rate of 42%
  • Change in modified Mayo Score of -3.7
  • Safety profile consistent with TL1A class; 2 SAEs deemed not drug-related, no drug-related SAEs, no deaths

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access